Open AccessAssociation ofHLA-C*06:02Status With Differential Response to Ustekinumab in Patients With Psoriasis
Author(s) -
Lieke J. van Vugt,
J.M.P.A. van den Reek,
Gerjon Hannink,
Marieke J. H. Coenen,
E.M.G.J. de Jong
Publication year - 2019
Publication title -
jama dermatology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.128
H-Index - 166
eISSN - 2168-6084
pISSN - 2168-6068
DOI - 10.1001/jamadermatol.2019.0098
Subject(s) - ustekinumab , medicine , psoriasis , dermatology , plaque psoriasis , association (psychology) , dermatologic agents , human leukocyte antigen , immunology , disease , adalimumab , antigen , genetics , philosophy , epistemology , biology , antibiotics
Previous research showed a differential response to ustekinumab therapy based on HLA-C*06:02 status in patients with psoriasis but consisted mostly of small (and sometimes inconclusive) cohort studies.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom